News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
627,105 Results
Type
Article (48118)
Company Profile (217)
Press Release (578770)
Multimedia
Podcasts (110)
Webinars (14)
Section
Business (177377)
Career Advice (2589)
Deals (32654)
Drug Delivery (124)
Drug Development (79114)
Employer Resources (164)
FDA (16347)
Job Trends (13666)
News (314158)
Policy (32555)
Tag
Academia (2429)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (84)
Alliances (44900)
ALS (97)
Alzheimer's disease (1465)
Antibody-drug conjugate (ADC) (152)
Approvals (16309)
Artificial intelligence (277)
Autoimmune disease (28)
Automation (12)
Bankruptcy (329)
Best Places to Work (10194)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (113)
Bladder cancer (82)
Brain cancer (29)
Breast cancer (284)
Cancer (2285)
Cardiovascular disease (193)
Career advice (2160)
Career pathing (34)
CAR-T (153)
Cell therapy (447)
Cervical cancer (20)
Clinical research (64496)
Collaboration (822)
Company closure (1)
Compensation (564)
Complete response letters (29)
COVID-19 (2673)
CRISPR (45)
C-suite (246)
Cystic fibrosis (99)
Data (2197)
Decentralized trials (2)
Denatured (27)
Depression (54)
Diabetes (284)
Diagnostics (5661)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (42)
Drug discovery (121)
Drug pricing (126)
Drug shortages (32)
Duchenne muscular dystrophy (99)
Earnings (70718)
Editorial (45)
Employer branding (20)
Employer resources (146)
Events (95465)
Executive appointments (718)
FDA (17675)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (701)
Gene editing (110)
Generative AI (24)
Gene therapy (332)
GLP-1 (828)
Government (4071)
Grass and pollen (6)
Guidances (105)
Healthcare (16045)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (144)
Indications (29)
Infectious disease (2828)
Inflammatory bowel disease (148)
Inflation Reduction Act (9)
Influenza (54)
Intellectual property (96)
Interviews (476)
IPO (15377)
IRA (49)
Job creations (3866)
Job search strategy (1808)
Kidney cancer (11)
Labor market (37)
Layoffs (529)
Leadership (24)
Legal (7888)
Liver cancer (78)
Lung cancer (322)
Lymphoma (154)
Machine learning (8)
Management (58)
Manufacturing (337)
MASH (76)
Medical device (11599)
Medtech (11603)
Mergers & acquisitions (17833)
Metabolic disorders (778)
Multiple sclerosis (87)
NASH (23)
Neurodegenerative disease (108)
Neuropsychiatric disorders (34)
Neuroscience (2050)
NextGen: Class of 2025 (5532)
Non-profit (3436)
Now hiring (30)
Obesity (427)
Opinion (260)
Ovarian cancer (71)
Pain (98)
Pancreatic cancer (85)
Parkinson's disease (157)
Partnered (18)
Patents (244)
Patient recruitment (112)
Peanut (46)
People (52548)
Pharmaceutical (89)
Pharmacy benefit managers (22)
Phase I (19880)
Phase II (28019)
Phase III (21834)
Pipeline (1302)
Policy (174)
Postmarket research (2610)
Preclinical (8107)
Press Release (50)
Prostate cancer (111)
Psychedelics (37)
Radiopharmaceuticals (244)
Rare diseases (412)
Real estate (5409)
Recruiting (65)
Regulatory (22854)
Reports (35)
Research institute (2232)
Resumes & cover letters (426)
Rett syndrome (4)
RNA editing (4)
RSV (47)
Schizophrenia (82)
Series A (128)
Series B (84)
Service/supplier (14)
Sickle cell disease (57)
Special edition (18)
Spinal muscular atrophy (154)
Sponsored (33)
Startups (3338)
State (2)
Stomach cancer (16)
Supply chain (74)
Tariffs (51)
The Weekly (81)
Vaccines (788)
Venture capitalists (43)
Weight loss (306)
Women's health (34)
Worklife (20)
Date
Today (287)
Last 7 days (856)
Last 30 days (2879)
Last 365 days (31846)
2025 (11271)
2024 (33902)
2023 (37956)
2022 (48577)
2021 (52358)
2020 (49729)
2019 (40560)
2018 (30960)
2017 (31274)
2016 (30064)
2015 (33729)
2014 (27400)
2013 (23041)
2012 (24703)
2011 (25297)
2010 (23250)
Location
Africa (786)
Alabama (45)
Alaska (7)
Arizona (190)
Arkansas (12)
Asia (39010)
Australia (6284)
California (5987)
Canada (1803)
China (512)
Colorado (263)
Connecticut (286)
Delaware (157)
Europe (88228)
Florida (902)
Georgia (187)
Hawaii (1)
Idaho (44)
Illinois (498)
India (27)
Indiana (273)
Iowa (11)
Japan (166)
Kansas (90)
Kentucky (22)
Louisiana (9)
Maine (64)
Maryland (898)
Massachusetts (4588)
Michigan (190)
Minnesota (357)
Mississippi (1)
Missouri (70)
Montana (18)
Nebraska (22)
Nevada (60)
New Hampshire (54)
New Jersey (1717)
New Mexico (26)
New York (1668)
North Carolina (982)
North Dakota (6)
Northern California (2654)
Ohio (176)
Oklahoma (10)
Oregon (32)
Pennsylvania (1303)
Puerto Rico (12)
Rhode Island (26)
South America (1164)
South Carolina (23)
South Dakota (1)
Southern California (2254)
Tennessee (93)
Texas (858)
United States (22481)
Utah (160)
Virginia (149)
Washington D.C. (67)
Washington State (539)
West Virginia (3)
Wisconsin (60)
627,105 Results for "galderma pharma s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
February 14, 2025
·
13 min read
Press Releases
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
February 18, 2025
·
7 min read
Tariffs
Trump’s Tariffs Could Challenge Pharma’s Recession-Resistant Reputation
Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as GLP-1s dominate and the population grows older.
April 8, 2025
·
5 min read
·
Annalee Armstrong
Press Releases
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
December 13, 2024
·
14 min read
Earnings
Pfizer CEO Calls Trump’s Pharma National Security Concerns ‘Legitimate’
Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the pharmaceutical industry tariffs, which Trump has threatened, in part as a way to shore up U.S. national security.
April 29, 2025
·
3 min read
·
Annalee Armstrong
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
C-suite
Pharma’s Biggest Golden Parachutes
Executives don’t just get paid big bucks to operate a company. Sometimes they get paid millions to walk away.
April 23, 2025
·
1 min read
·
Annalee Armstrong
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
·
7 min read
·
Annalee Armstrong
Government
Trump’s Whiplash Policies Keep Pharmas on Their Toes
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.
February 12, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
November 28, 2024
·
10 min read
1 of 62,711
Next
